Successful treatment of recurrent renal stones with Cinacalcet in a patient with primary hyperparathyroidism by Chauhan, Priyesh et al.
 
 
University of Birmingham
Successful treatment of recurrent renal stones with
Cinacalcet in a patient with primary
hyperparathyroidism
Chauhan, Priyesh; Gittoes, Neil; Geberhiwot, Tarekegn
DOI:
10.1136/bcr-2016-216311
License:
None: All rights reserved
Document Version
Peer reviewed version
Citation for published version (Harvard):
Chauhan, P, Gittoes, N & Geberhiwot, T 2016, 'Successful treatment of recurrent renal stones with Cinacalcet in
a patient with primary hyperparathyroidism', BMJ case reports. https://doi.org/10.1136/bcr-2016-216311
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Author can archive post-print (ie final draft post-refereeing) on author's personal website, institutional website or institutional repository
immediately upon online publication. Eligibility for repository: Checked on 12/10/2016
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
Queries for Author
Journal: BMJ Case Reports
Paper: bcr-2016-216311
Title: Successful treatment of recurrent renal stones with Cinacalcet in a patient with primary
hyperparathyroidism
The proof of your manuscript appears on the following page(s).
It is the responsibility of the corresponding author to check against the original manuscript and approve or
amend these proofs.
Please read the proofs carefully, checking for accuracy, verifying the reference order and checking ﬁgures and
tables. When reviewing your page proof please keep in mind that a professional copyeditor edited your
manuscript to comply with the style requirements of the journal.
This is not an opportunity to alter, amend or revise your paper; it is intended to be for correction purposes
only. The journal reserves the right to charge for excessive author alterations or for changes requested after the
prooﬁng stage has concluded.
During the preparation of your manuscript for publication, the questions listed below have arisen (the query
number can also be found in the gutter close to the text it refers to). Please attend to these matters and return
the answers to these questions when you return your corrections.
Please note, we will not be able to proceed with your article if these queries have not been addressed.
A second proof is not normally provided.
Note Reference Note
N1 IMPORTANT: Corrections at this stage should be limited to those that are essential.
Extensive corrections will delay the time to publication and may also have to be approved
by the Editor. Alterations cannot be made after the article has published online.
N2 Author SURNAMES (family names) have been highlighted - please check that these are
correct. Please check all names are spelt correctly, and that afﬁliations and correspondence
details are accurate.
N3 Your article should display in PubMed within 2 working days of publication.
Query Reference Query
Q1 Please check whether the phrase ‘drug’s understood mechanism of action’ provides
intended meaning.
If you are happy with the proof as it stands, please email to conﬁrm this. Minor changes that do not require a
copy of the proof can be sent by email (please be as speciﬁc as possible).
Email: production.bmjcases@bmj.com
If you have any changes that cannot be described easily in an email, please mark them clearly on the proof using
the annotation tools and email this by reply to the eProof email.
PE: JKM CE: KA QC: LM
Author query sheet
We will keep a copy of any correspondence from you related to the author proof for six months. After six
months, correspondence will be deleted.
Please respond within 48 hours
Author query sheet
CASE REPORT
SuccessfulN1
¶N2
¶
treatment of recurrent renal stones
with Cinacalcet in a patient with primary
hyperparathyroidismN3
¶
Priyesh Chauhan,1 Neil J Gittoes,2 Tarekegn Geberhiwot3
1Department of Endocrinology,
University of Birmingham,
Birmingham, UK
2University of Birmingham,
Birmingham, UK
3Department of Endocrinology,
University Hospital of
Birmingham, Birmingham, UK
Correspondence to
Dr Tarekegn Geberhiwot,
Tarekegn.hiwot@uhb.nhs.uk
Accepted 26 July 2016
To cite: Chauhan P,
Gittoes NJ, Geberhiwot T.
BMJ Case Rep Published
online: [please include Day
Month Year] doi:10.1136/
bcr-2016-216311
SUMMARY
A man aged 72 years with long-standing primary
hyperparathyroidism (HPT), a background of recurrent
bilateral renal stones and failed parathyroid surgery is
described. During the 27 months preceding treatment,
episodes of renal colic became increasingly frequent and
he required multiple surgical interventions. Given the
lack of medical therapies to deﬁnitively treat his
symptoms, he was started on a trial of the calcimimetic,
Cinacalcet. Cinacalcet has previously been shown to
reduce hypercalcaemia in patients with primary HPT.
Despite this, there is a paucity of evidence to suggest
that its use is associated with a long-term reduction in
urinary calcium excretion and renal stone recurrence. In
our case, within 4 months of starting treatment, serum
and urinary calcium had normalised and parathyroid
hormone concentrations were within reference ranges. To
date, over a 50-month treatment period, there has been
a complete cessation in stone formation, and no further
urological intervention has been required.
BACKGROUND
A recent prospective study identiﬁed that 55% of
all patients with primary hyperparathyroidism
(HPT) showed evidence of stone formation on
renal ultrasound assessment.1 Renal and urinary
tract stones are therefore a relatively common com-
plication of long-standing hypercalcaemia.
Parathyroidectomy remains the deﬁnitive gold-
standard treatment for patients with primary HPT
and target organ involvement. In patients who are
deemed unsuitable for parathyroid surgery, conser-
vative management should be considered; the
mainstay of which is ensuring adequate hydration
to minimise the risk of renal stone formation.
Additionally, as part of regular outpatient monitor-
ing, renal ultrasound scans, renal function tests,
bone mineral density scans and urinary calcium
excretion tests should be performed to actively
screen for target organ damage.
In our case, a combination of failed parathyroid
surgery and a disappointing response to conserva-
tive management resulted in consideration of a trial
of Cinacalcet. We believe that for this subgroup of
patients, where treatment options remain limited,
there is currently an unmet need for a deﬁnitive
medical therapy. Cinacalcet, a second-generation
calcimimetic drug, was approved by the European
Medicines Agency in June 2008 as a medical treat-
ment of hypercalcaemia in patients with primary
HPT.2 3 In our patient, initiation of Cinacalcet
dramatically reduced urinary calcium excretion and
renal stone recurrence.
CASE PRESENTATION
The patient we present is a Caucasian man aged 72
years. At the age of 43, after suffering from an
episode of severe renal colic, which warranted sur-
gical intervention with an open pyelolithotomy,
routine blood tests revealed a serum hypercalcae-
mia and an inappropriately elevated serum parathy-
roid hormone (PTH) concentration; these results
were consistent with a diagnosis of primary HPT.
There was no signiﬁcant medical history. The
patient subsequently underwent an elective parathy-
roid exploration, which was unsuccessful in locat-
ing the suspected parathyroid adenoma. As a direct
complication of the procedure, the patient sus-
tained a recurrent laryngeal nerve palsy resulting in
unilateral vocal cord paralysis. Prior to this surgery,
no formal localisation studies were conducted.
Following the attempted parathyroidectomy, a
99m-technetium sestamibi scan failed to demon-
strate any abnormal uptake in the neck or mediasti-
num, despite persistently elevated PTH levels.
Given the grossly normal operative appearance of
the parathyroid glands, it was suggested that the
true source of PTH secretion could be ectopic in
origin; however, this was never deﬁnitively proven.
The patient declined any further surgery.
Over the next 25 years, he suffered from mul-
tiple episodes of renal colic, which appeared to be
increasing in frequency. During this time, he passed
six renal stones spontaneously while larger stones,
up to 20 mm in size, required surgical intervention.
In total, the patient underwent four percutaneous
nephrolithotomy procedures.
INVESTIGATIONS
Renal stone analysis undertaken in 2011 revealed
that calcium oxalate crystals were a predominant
constituent. Throughout his long follow-up, the
patient’s serum calcium was consistently elevated,
between 2.8 and 2.99 mmol/L, whereas his PTH
concentration ﬂuctuated (mean PTH: 7.8 pmol/L)
and peaked at 10.9 pmol/L. Prior to the initiation
of Cinacalcet, a 24-hour urine calcium excretion
test was performed, and this was recorded as
17.2 mmol/24 hours. No other urinary calcium
tests were performed during this pretreatment
period. Other biochemical parameters, including
estimated glomerular ﬁltration rate and 25-hydroxy
vitamin D, were within normal ranges.
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TREATMENT
Given the increasing risk of further stone formation and asso-
ciated complications, such as renal failure, ureteric strictures and
pyelonephritis,4 we sought to ﬁnd an intervention to moderate
his ongoing symptoms. However, the apparent lack of deﬁnitive
medical therapies for patients with long-standing HPT resulted
in consideration of a trial of Cinacalcet at a dose of 30 mg twice
daily, which was started in April 2011.
OUTCOME AND FOLLOW-UP
By July 2011, serum calcium and PTH levels had normalised to
2.5 mmol/L and 5.9 pmol/L, respectively. Further surveillance of
his bone proﬁle in recent years also revealed serum calcium and
PTH concentrations within reference ranges; in December
2015, these were 2.4 mmol/L and 6.5 pmol/L, respectively.
There was a marked reduction in 24-hour urinary calcium
excretion from the 17.2 mmol/24 hours in June 2004 (pretreat-
ment) to 7.4 mmol/24 hours in January 2013 (during treat-
ment). In April 2015, this had changed marginally to 8.7 mmol/
24 hours. This has been mirrored by the complete cessation of
nephrocalcinosis, since starting Cinacalcet, for a period of
50 months. The patient has not passed any further stones,
remains asymptomatic and has not required any additional uro-
logical intervention.
DISCUSSION
Primary HPT is the most common cause of hypercalcemia.5
Most patients are asymptomatic at diagnosis, and their manage-
ment is generally conservative. However, a small subgroup may
present with target organ involvement, such as renal stones or
osteoporosis, and may require a parathyroidectomy. If surgery is
contraindicated or the patient refuses the procedure, then
patients with osteoporosis may receive antiresorptive agents;
currently, there is no alternative equivalent for patients with
symptomatic renal stones. Cinacalcet is a second-generation cal-
cimimetic that acts as an allosteric modulator of calcium-sensing
receptors (CaSRs) in the parathyroid glands. It is also thought
to act on CaSRs expressed at bone and renal levels.3 6 By
increasing CaSR sensitivity to extracellular calcium, it suppresses
PTH secretion and thereby reduces serum calcium
concentrations.3
It is difﬁcult to establish the exact effect of Cinacalcet on
urinary calcium for a variety of reasons.7 At a renal tubular
level, PTH acts to increase calcium reabsorption from the glom-
erular ﬁltrate. Therefore, as Cinacalcet suppresses PTH levels it
should act to increase urinary calcium. This is counteracted by a
reduction in serum calcium and the ﬁltered load of calcium,
which should lead to a decrease in urinary calcium. The overall
effect of Cinacalcet on urinary calcium excretion should there-
fore be almost negligible.7
In patients with primary HPT, serum hypercalcaemia activates
CaSRs in the kidneys resulting in a decreased renal tubular
calcium reabsorption and an overall urinary dilution, which
ultimately helps to protect against stone formation.8 It is likely
that patients with HPTand a predisposition to renal stone devel-
opment have a deactivating CaSR allelic variant.8 This provides
a likely explanation as to why our patient responded so favour-
ably to Cinacalcet, given thisQ1 drug’s understood mechanism of
action.3 6
At present, there appears to be very little evidence in the lit-
erature to suggest that the use of Cinacalcet can be associated
with a reduction in the rate of renal stone formation. However,
a pilot study conducted by Brardi et al9 demonstrated a statistic-
ally signiﬁcant reduction in the overall number and diameter of
renal stones in a small sample of patients with a background of
primary HPT and active nephrolithiasis. They were treated with
Cinacalcet for a period of 10 months. Similarly, an audit under-
taken by Moyes et al10 showed that patients with multiple endo-
crine neoplasia type 1, primary HPT and a history of renal
calculi demonstrated no recurrence of renal stone formation
after taking Cinacalcet for an average duration of 23 months.
In contrast, Seager et al3 reported the ﬁrst well-documented
case of Cinacalcet use directly contributing to the development
of renal stones in a post-transplant patient with HPT. It should
be noted that Seager et al3 make reference to the fact that the
use of calcineurin inhibitors and prednisone as immunosuppres-
sive agents could have contributed to the increased renal
calcium load and urinary excretion. Thus, a deﬁnitive causal
link between Cinacalcet use and renal stone formation cannot
easily be established; it appears that the case presented by
Seager et al3 is indeed exceptional.
Our case demonstrates a potential use of Cinacalcet as a
longer term medical therapy for patients with primary HPT and
recurrent renal stones who are unsuitable for parathyroidect-
omy. More data are required to determine whether this observa-
tion is generalisable.
Patient’s perspective
After many years suffering from kidney stones and undergoing
several operations to have them removed, it was a great relief
to ﬁnally come into contact with people who suggested a way
of reducing the calcium levels in my blood. I am grateful to the
friendly team at Queen Elizabeth Hospital, Birmingham, for the
treatment and the positive outcome achieved.
Learning points
▸ Long-term treatment with Cinacalcet resulted in a
normalisation of biochemical parameters in a patient with
primary HPT.
▸ Use of Cinacalcet was associated with a reduction in renal
stone formation in a patient with primary HPT over a
50-month period.
▸ Cinacalcet may have a role in the treatment of patients with
primary HPT and recurrent renal stones who are unsuitable
for parathyroidectomy.
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